FindTrial
Sign In

Role of MCT8 in pregnant ladies

Role of placental monocarboxylate transporter 8 (MCT8) expression on adverse pregnancy outcomes in Indian population.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/10/037593
Enrollment
276
Registered
2021-10-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Indian Council of Medical Research ICMR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Pregnant ladies first, second, third trimester of age group 18-38 years

Exclusion criteria

Exclusion criteria: Chronic hypertension, overt diabetes, IVF pregnancy, multifetal gestation, thyroid cancer/ thyroidectomy/ any surgery of thyroid

Design outcomes

Primary

MeasureTime frame
To measure the MCT 8 expression in placenta of patients with a known adverse pregnancy outcome after delivery and to compare with various clinical factorsTimepoint: 2 years—

Secondary

MeasureTime frame
To evaluate the impact of MCT 8 expression across different adverse pregnancy outcomes and its relation to maternal thyroid hormone status.Timepoint: 3 years—

Countries

India

Contacts

Public ContactDr Mahadev Rao

Manipal Academy of Higher Education

mahadev.rao@manipal.edu8105706060

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026